BioSpace4m
Adcendo Rides ADC Wave With $135M Series B
Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.
BioSpace21m
Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...